Trending News

Human brain
#Mergers and acquisitions #Neuropsychiatric disorders #Neuroscience #Postpartum depression #Sage Therapeutics #Supernus Pharmaceuticals

Supernus acquires Sage to strengthen neuropsychiatry portfolio

Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a collaboration agreement with Biogen, Supernus… Read More

#Business & Investment #News #Trending News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer Research UK #Gene mutation #Oncology

New approach shows promise in aggressive breast cancers

A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.  In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More

#Cancer Research #News #Trending News

Covid-19
#Covid-19 #Immunology / Virology & Vaccines #Preclinical development #Rocketvax #SARS-CoV-2

Robust preclinical results for live-attenuated SARS-CoV-2 vaccine

Live-attenuated SARS-CoV-2 vaccine candidate, OTS-228, has demonstrated exceptional safety, efficacy, and genomic stability in preclinical animal models.  The vaccine was developed under the scientific leadership of Professor Dr Volker Thiel, Chief Scientist of Rocketvax and Professor of Virology at the University of Bern.  The latest… Read More

#News #Trending News

UK financial markets
#Association of the British Pharmaceutical Industry #Investment #Pharmaceutical industry #Research and development #UK #UK government

UK to lose £11bn in pharma R&D investment

The UK could lose out on £11 ($14.8) billion in pharmaceuticals research and development (R&D) investment by 2033, according to WPI Economics.  In the UK, the Voluntary Scheme or VPAG requires companies to pay the Department of Health and Social Care (DHSC) up to a quarter to a third of… Read More

#Business & Investment #News #Trending News

Breast cancer
#ASCO #AstraZeneca #Breast cancer #Oncology #The Institute of Cancer Research

Camizestrant reduces risk of breast cancer progression by 56%

Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.  The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More

#Cancer Research #News #Trending News

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated… Read More

#Business & Investment #News #Trending News

Close up of vaccine syringe
#Bacteria #Immunology / Virology & Vaccines #University of Oxford #Viral vectors

Gene-based vaccine shows promise in early-stage trial

Trial results have revealed encouraging results for a new vaccine targeting group B meningococcus (MenB) and established that a gene-based vaccine platform can induce protective antibody responses against bacteria.  The investigational vaccine, ChAdOx1 MenB.1, developed by researchers at the University of Oxford, was shown to be safe… Read More

#News #Trending News

EU flag
#European Commission #European Union #Funding #Research and development

EC urges researchers to “choose Europe for science”

European Commission President Ursula von der Leyen has announced new funding ‘super grants’ at the ‘Choose Europe for Science’ conference.  The substantial additional budget for the development of larger, longer-term grants has been welcomed by the Scientific Council of the European Research Council (ERC).   As… Read More

#News #Trending News

Human neuron
#Amyotrophic lateral sclerosis (ALS) #Early access #FDA #Neuroscience #Spinogenix

FDA okays access programme for ALS synaptic regenerative therapy

The Food and Drug Administration (FDA) has authorised Spinogenix to begin its Expanded Access Program (EAP) for SPG302 in the United States for people with amyotrophic lateral sclerosis (ALS) that meet programme eligibility criteria.  SPG302 is being developed as the first synaptic regenerative approach to treating ALS, with the potential… Read More

#News #Regulatory #Trending News

Liver cancer
#Macrophages #Oncology #Phase I trial #Pheast Therapeutics #Solid tumours

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.  The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours.  The study’s primary objectives… Read More

#Cancer Research #News #Trending News

Woman tests blood glucose level
#Diabetes #Immunotherapy #Type 1 diabetes #University of Queensland

Pioneering clinical trial of immunotherapy for type 1 diabetes

Researchers at The University of Queensland (UQ) have launched the first clinical trial of a potentially revolutionary immunotherapy drug to treat type 1 diabetes.  Professor Ranjeny Thomas from UQ’s Frazer Institute has led the development of a targeted immunotherapy drug, ASITI-201, which has been designed to rebalance… Read More

#News #Trending News

Epidermolysis bullosa patient has foot bandaged
#Abeona Therapeutics #Epidermolysis bullosa #FDA #Gene therapy

Gene therapy for severe skin disease secures historic approval

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel.  Zevaskyn is an autologous cell-based gene therapy for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).  “Today’s approval of Zevaskyn represents a… Read More

#News #Regulatory #Trending News